211 related articles for article (PubMed ID: 36578022)
1. Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer's disease protects against mitochondrial dysfunction and mitigates brain pathology.
Verma A; Shteinfer-Kuzmine A; Kamenetsky N; Pittala S; Paul A; Nahon Crystal E; Ouro A; Chalifa-Caspi V; Pandey SK; Monsonego A; Vardi N; Knafo S; Shoshan-Barmatz V
Transl Neurodegener; 2022 Dec; 11(1):58. PubMed ID: 36578022
[TBL] [Abstract][Full Text] [Related]
2. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
3. VDAC1, mitochondrial dysfunction, and Alzheimer's disease.
Shoshan-Barmatz V; Nahon-Crystal E; Shteinfer-Kuzmine A; Gupta R
Pharmacol Res; 2018 May; 131():87-101. PubMed ID: 29551631
[TBL] [Abstract][Full Text] [Related]
4. The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy.
Smilansky A; Dangoor L; Nakdimon I; Ben-Hail D; Mizrachi D; Shoshan-Barmatz V
J Biol Chem; 2015 Dec; 290(52):30670-83. PubMed ID: 26542804
[TBL] [Abstract][Full Text] [Related]
5. The role of the mitochondrial protein VDAC1 in inflammatory bowel disease: a potential therapeutic target.
Verma A; Pittala S; Alhozeel B; Shteinfer-Kuzmine A; Ohana E; Gupta R; Chung JH; Shoshan-Barmatz V
Mol Ther; 2022 Feb; 30(2):726-744. PubMed ID: 34217890
[TBL] [Abstract][Full Text] [Related]
6. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease?
Reddy PH
Biochim Biophys Acta; 2013 Jan; 1832(1):67-75. PubMed ID: 22995655
[TBL] [Abstract][Full Text] [Related]
7. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.
Fernandez-Echevarria C; Díaz M; Ferrer I; Canerina-Amaro A; Marin R
Neuroscience; 2014 Oct; 278():354-66. PubMed ID: 25168729
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS.
Shteinfer-Kuzmine A; Argueti-Ostrovsky S; Leyton-Jaimes MF; Anand U; Abu-Hamad S; Zalk R; Shoshan-Barmatz V; Israelson A
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077343
[TBL] [Abstract][Full Text] [Related]
9. Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction.
Ben-Hail D; Begas-Shvartz R; Shalev M; Shteinfer-Kuzmine A; Gruzman A; Reina S; De Pinto V; Shoshan-Barmatz V
J Biol Chem; 2016 Nov; 291(48):24986-25003. PubMed ID: 27738100
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of VDAC1 Rescues A
Zhou X; Tang X; Li T; Li D; Gong Z; Zhang X; Li Y; Zhu J; Wang Y; Zhang B
Mediators Inflamm; 2023; 2023():6739691. PubMed ID: 36816741
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid-β.
Cuadrado-Tejedor M; Vilariño M; Cabodevilla F; Del Río J; Frechilla D; Pérez-Mediavilla A
J Alzheimers Dis; 2011; 23(2):195-206. PubMed ID: 20930307
[TBL] [Abstract][Full Text] [Related]
12. Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies.
Manczak M; Sheiko T; Craigen WJ; Reddy PH
J Alzheimers Dis; 2013; 37(4):679-90. PubMed ID: 23948905
[TBL] [Abstract][Full Text] [Related]
13. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Drp1 Ameliorates Synaptic Depression, Aβ Deposition, and Cognitive Impairment in an Alzheimer's Disease Model.
Baek SH; Park SJ; Jeong JI; Kim SH; Han J; Kyung JW; Baik SH; Choi Y; Choi BY; Park JS; Bahn G; Shin JH; Jo DS; Lee JY; Jang CG; Arumugam TV; Kim J; Han JW; Koh JY; Cho DH; Jo DG
J Neurosci; 2017 May; 37(20):5099-5110. PubMed ID: 28432138
[TBL] [Abstract][Full Text] [Related]
15. Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer's Disease.
Vijayan M; Reddy PH
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955694
[TBL] [Abstract][Full Text] [Related]
16. Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage.
Reddy PH
Biochim Biophys Acta; 2013 Dec; 1832(12):1913-21. PubMed ID: 23816568
[TBL] [Abstract][Full Text] [Related]
17. RNA silencing of genes involved in Alzheimer's disease enhances mitochondrial function and synaptic activity.
Manczak M; Reddy PH
Biochim Biophys Acta; 2013 Dec; 1832(12):2368-78. PubMed ID: 24063855
[TBL] [Abstract][Full Text] [Related]
18. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis.
Lee HJ; Jung YH; Choi GE; Kim JS; Chae CW; Lim JR; Kim SY; Yoon JH; Cho JH; Lee SJ; Han HJ
Cell Death Differ; 2021 Jan; 28(1):184-202. PubMed ID: 32704090
[TBL] [Abstract][Full Text] [Related]
19. Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.
Du F; Yu Q; Yan S; Zhang Z; Vangavaragu JR; Chen D; Yan SF; Yan SS
Aging Cell; 2021 May; 20(5):e13368. PubMed ID: 33951271
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of hesperidin against amyloid-β (Aβ) induced neurotoxicity through the voltage dependent anion channel 1 (VDAC1)-mediated mitochondrial apoptotic pathway in PC12 cells.
Wang DM; Li SQ; Zhu XY; Wang Y; Wu WL; Zhang XJ
Neurochem Res; 2013 May; 38(5):1034-44. PubMed ID: 23475456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
